peri-operative treatment for gastric cancer · reasons for peri-operative • significant benefit...
TRANSCRIPT
![Page 1: Peri-operative Treatment for Gastric Cancer · Reasons for peri-operative • Significant benefit with 3 cycles of pre-operative chemotherapy • Post-operative patients may not be](https://reader034.vdocuments.site/reader034/viewer/2022042112/5e8e046552395b744e22856d/html5/thumbnails/1.jpg)
Peri-operative Treatment for Gastric Cancer
Howard LimMedical Oncologist
B.C. Cancer Agency
![Page 2: Peri-operative Treatment for Gastric Cancer · Reasons for peri-operative • Significant benefit with 3 cycles of pre-operative chemotherapy • Post-operative patients may not be](https://reader034.vdocuments.site/reader034/viewer/2022042112/5e8e046552395b744e22856d/html5/thumbnails/2.jpg)
Disclosures
• I have no financial disclosures or conflicts of interest
• If I did I would be able to afford a house in Vancouver
![Page 3: Peri-operative Treatment for Gastric Cancer · Reasons for peri-operative • Significant benefit with 3 cycles of pre-operative chemotherapy • Post-operative patients may not be](https://reader034.vdocuments.site/reader034/viewer/2022042112/5e8e046552395b744e22856d/html5/thumbnails/3.jpg)
![Page 4: Peri-operative Treatment for Gastric Cancer · Reasons for peri-operative • Significant benefit with 3 cycles of pre-operative chemotherapy • Post-operative patients may not be](https://reader034.vdocuments.site/reader034/viewer/2022042112/5e8e046552395b744e22856d/html5/thumbnails/4.jpg)
Esophagus and Stomach
![Page 5: Peri-operative Treatment for Gastric Cancer · Reasons for peri-operative • Significant benefit with 3 cycles of pre-operative chemotherapy • Post-operative patients may not be](https://reader034.vdocuments.site/reader034/viewer/2022042112/5e8e046552395b744e22856d/html5/thumbnails/5.jpg)
Question
• Is there a preferred perioperative treatment for patients with gastric cancer?
![Page 6: Peri-operative Treatment for Gastric Cancer · Reasons for peri-operative • Significant benefit with 3 cycles of pre-operative chemotherapy • Post-operative patients may not be](https://reader034.vdocuments.site/reader034/viewer/2022042112/5e8e046552395b744e22856d/html5/thumbnails/6.jpg)
6
Surgery
![Page 7: Peri-operative Treatment for Gastric Cancer · Reasons for peri-operative • Significant benefit with 3 cycles of pre-operative chemotherapy • Post-operative patients may not be](https://reader034.vdocuments.site/reader034/viewer/2022042112/5e8e046552395b744e22856d/html5/thumbnails/7.jpg)
7
EsophagealSCC(%)
EsophagealAdeno-CA
(%)
GastricAdeno-CA
(%)
pT1MucosaSubmucosa
pT2pT3pT4
10091847048
100100846859
10098876041
The Goal – R0 Resection
Siewert et al. in Kelsen (Ed.) GI Oncology 2002; Table 18-3Siewert et al. Ann Surg 1998; 228: 449-461
![Page 8: Peri-operative Treatment for Gastric Cancer · Reasons for peri-operative • Significant benefit with 3 cycles of pre-operative chemotherapy • Post-operative patients may not be](https://reader034.vdocuments.site/reader034/viewer/2022042112/5e8e046552395b744e22856d/html5/thumbnails/8.jpg)
Stomach Surgery - Lymphadenectomy
D1 nodes adjacent to the stomach
D2 + branches celiac axis
D3 nodes along the aorta
![Page 9: Peri-operative Treatment for Gastric Cancer · Reasons for peri-operative • Significant benefit with 3 cycles of pre-operative chemotherapy • Post-operative patients may not be](https://reader034.vdocuments.site/reader034/viewer/2022042112/5e8e046552395b744e22856d/html5/thumbnails/9.jpg)
D1 versus D2 Lymphadenectomy
Hartgrink et al., J Clin Oncol 2004;22:2069-2077
Morbidity 25% v 43%; P = .001
Mortality 4% v 10%; P = .004
Morbidity and mortality influenced
- pancreatectomy- splenectomy- and age
![Page 10: Peri-operative Treatment for Gastric Cancer · Reasons for peri-operative • Significant benefit with 3 cycles of pre-operative chemotherapy • Post-operative patients may not be](https://reader034.vdocuments.site/reader034/viewer/2022042112/5e8e046552395b744e22856d/html5/thumbnails/10.jpg)
D1 versus D2 Lymphadenectomy
Hartgrink et al., J Clin Oncol 2004;22:2069-2077
Subgroup with N2 diseaseSubgroup with N2 disease
![Page 11: Peri-operative Treatment for Gastric Cancer · Reasons for peri-operative • Significant benefit with 3 cycles of pre-operative chemotherapy • Post-operative patients may not be](https://reader034.vdocuments.site/reader034/viewer/2022042112/5e8e046552395b744e22856d/html5/thumbnails/11.jpg)
D1 versus D3 Lymphadenectomy
Wu et al. Lancet Oncol 2006;7:309–15
“D3 nodal dissection, compared with that of D1,offers a survival benefit for patients with gastric cancerwhen done by well trained, experienced surgeons.”
![Page 12: Peri-operative Treatment for Gastric Cancer · Reasons for peri-operative • Significant benefit with 3 cycles of pre-operative chemotherapy • Post-operative patients may not be](https://reader034.vdocuments.site/reader034/viewer/2022042112/5e8e046552395b744e22856d/html5/thumbnails/12.jpg)
12
![Page 13: Peri-operative Treatment for Gastric Cancer · Reasons for peri-operative • Significant benefit with 3 cycles of pre-operative chemotherapy • Post-operative patients may not be](https://reader034.vdocuments.site/reader034/viewer/2022042112/5e8e046552395b744e22856d/html5/thumbnails/13.jpg)
BC Experience
Figure 5 – Kaplan-Meier survival curves comparing margins
![Page 14: Peri-operative Treatment for Gastric Cancer · Reasons for peri-operative • Significant benefit with 3 cycles of pre-operative chemotherapy • Post-operative patients may not be](https://reader034.vdocuments.site/reader034/viewer/2022042112/5e8e046552395b744e22856d/html5/thumbnails/14.jpg)
BC Experience
Figure 3 – Kaplan-Meier survival curves comparing lymph node ratio. < 0.2 vs > 0.2
![Page 15: Peri-operative Treatment for Gastric Cancer · Reasons for peri-operative • Significant benefit with 3 cycles of pre-operative chemotherapy • Post-operative patients may not be](https://reader034.vdocuments.site/reader034/viewer/2022042112/5e8e046552395b744e22856d/html5/thumbnails/15.jpg)
BC Experience
Figure 4 – Kaplan-Meier survival curves comparing use of perioperative treatment. a indicates chemotherapy +/- radiation, n indicates no
treatment
![Page 16: Peri-operative Treatment for Gastric Cancer · Reasons for peri-operative • Significant benefit with 3 cycles of pre-operative chemotherapy • Post-operative patients may not be](https://reader034.vdocuments.site/reader034/viewer/2022042112/5e8e046552395b744e22856d/html5/thumbnails/16.jpg)
16
Key to Gastric Cancer
• Surgery is the key for curative intent treatment
• Chemotherapy and Radiation do not make up for inadequate surgery
• Peri-operative treatment still confers a survival benefit
![Page 17: Peri-operative Treatment for Gastric Cancer · Reasons for peri-operative • Significant benefit with 3 cycles of pre-operative chemotherapy • Post-operative patients may not be](https://reader034.vdocuments.site/reader034/viewer/2022042112/5e8e046552395b744e22856d/html5/thumbnails/17.jpg)
17
Peri-operative chemotherapy
![Page 18: Peri-operative Treatment for Gastric Cancer · Reasons for peri-operative • Significant benefit with 3 cycles of pre-operative chemotherapy • Post-operative patients may not be](https://reader034.vdocuments.site/reader034/viewer/2022042112/5e8e046552395b744e22856d/html5/thumbnails/18.jpg)
18
UK MAGIC Trial
St. II + IIIGastric +Junction +EsophagusN = 5031994-2002
St. II + IIIGastric +Junction +EsophagusN = 5031994-2002
RANDOM
Chemotherapy:ECF x 3 Resection ECF x 3Chemotherapy:ECF x 3 Resection ECF x 3
Surgery aloneSurgery alone
Primary endpoint: 5-y-survival
*ECF: Epirubicin 50mg/m2 d1, Cisplatin 60mg/m2 d1, 5-FU 200mg/m2/d cont iv, qd 22
Cunningham D et al. N Engl J Med 2006;355:11-20
![Page 19: Peri-operative Treatment for Gastric Cancer · Reasons for peri-operative • Significant benefit with 3 cycles of pre-operative chemotherapy • Post-operative patients may not be](https://reader034.vdocuments.site/reader034/viewer/2022042112/5e8e046552395b744e22856d/html5/thumbnails/19.jpg)
19
![Page 20: Peri-operative Treatment for Gastric Cancer · Reasons for peri-operative • Significant benefit with 3 cycles of pre-operative chemotherapy • Post-operative patients may not be](https://reader034.vdocuments.site/reader034/viewer/2022042112/5e8e046552395b744e22856d/html5/thumbnails/20.jpg)
20
![Page 21: Peri-operative Treatment for Gastric Cancer · Reasons for peri-operative • Significant benefit with 3 cycles of pre-operative chemotherapy • Post-operative patients may not be](https://reader034.vdocuments.site/reader034/viewer/2022042112/5e8e046552395b744e22856d/html5/thumbnails/21.jpg)
21Cunningham D et al. N Engl J Med 2006;355:11-20
UK MAGIC Trial
CTX SURG P-value
MaximalDiameter 3 cm 5 cm <
0.001
(y)pT1/2 51.7% 36.8% 0.002
(y)pN0/1 84.4% 70.5% 0.01
![Page 22: Peri-operative Treatment for Gastric Cancer · Reasons for peri-operative • Significant benefit with 3 cycles of pre-operative chemotherapy • Post-operative patients may not be](https://reader034.vdocuments.site/reader034/viewer/2022042112/5e8e046552395b744e22856d/html5/thumbnails/22.jpg)
22
Chemotherapy250 pts assigned to chemotherapy (86%
completed all 3 cycles)
209 pts underwent surgery
137 pts proceeded to post-op chemotherapy
37 pts disease progression
10 post-op complications
11 pt choice
2 lack of response
9 Other
104 pts completed post-op chemotherapy (41.6% of 250 pts initially assigned)
- After surgery – no increase in grade 3/4 toxicity
![Page 23: Peri-operative Treatment for Gastric Cancer · Reasons for peri-operative • Significant benefit with 3 cycles of pre-operative chemotherapy • Post-operative patients may not be](https://reader034.vdocuments.site/reader034/viewer/2022042112/5e8e046552395b744e22856d/html5/thumbnails/23.jpg)
23
Surgery Details
• Chemotherapy group – 229 (91.6%) pts went for surgery
• Surgery within 3-6 weeks of completion of chemotherapy
• Post-operative complications were similar (45.7% vs 45.3%; chemo vs. no chemo), number of deaths at 30 days (5.6% vs 5.9%) and median stay in hospital 13 days both groups.
![Page 24: Peri-operative Treatment for Gastric Cancer · Reasons for peri-operative • Significant benefit with 3 cycles of pre-operative chemotherapy • Post-operative patients may not be](https://reader034.vdocuments.site/reader034/viewer/2022042112/5e8e046552395b744e22856d/html5/thumbnails/24.jpg)
24Cunningham D et al. N Engl J Med 2006;355:11-20
23%
5-y-OS
UK MAGIC Trial
36%
![Page 25: Peri-operative Treatment for Gastric Cancer · Reasons for peri-operative • Significant benefit with 3 cycles of pre-operative chemotherapy • Post-operative patients may not be](https://reader034.vdocuments.site/reader034/viewer/2022042112/5e8e046552395b744e22856d/html5/thumbnails/25.jpg)
25
St. II + IIIGastric +Junction +N = 2241995-2003
St. II + IIIGastric +Junction +N = 2241995-2003
RANDOM
Chemotherapy:CF x 2 Resection CF x 4Chemotherapy:CF x 2 Resection CF x 4
Surgery aloneSurgery alone
*CF: Cisplatin 100mg/m2 d1, 5-FU 800mg/m2/d d1-5, qd 28
Primary endpoint: Survival20% 35% after 5 years, α=5%, β=20%
Boige, V. et al. ASCO 2007 #4510
France FNCC 94012 France FNCC 94012 -- FFCD 9703 FFCD 9703
![Page 26: Peri-operative Treatment for Gastric Cancer · Reasons for peri-operative • Significant benefit with 3 cycles of pre-operative chemotherapy • Post-operative patients may not be](https://reader034.vdocuments.site/reader034/viewer/2022042112/5e8e046552395b744e22856d/html5/thumbnails/26.jpg)
26
France FNCC 94012 France FNCC 94012 -- FFCD 9703 FFCD 9703
Boige, V. et al. ASCO 2007 #4510
5-year-survival: 24% (16-33%) vs 38% (28-47%)
713162738537911114172741536593113
0,00
0,20
0,40
0,60
0,80
1,00
0 1 2 3 4 5 6 7A risque
logrank : p = 0,021
![Page 27: Peri-operative Treatment for Gastric Cancer · Reasons for peri-operative • Significant benefit with 3 cycles of pre-operative chemotherapy • Post-operative patients may not be](https://reader034.vdocuments.site/reader034/viewer/2022042112/5e8e046552395b744e22856d/html5/thumbnails/27.jpg)
27
Adjuvant Treatment
![Page 28: Peri-operative Treatment for Gastric Cancer · Reasons for peri-operative • Significant benefit with 3 cycles of pre-operative chemotherapy • Post-operative patients may not be](https://reader034.vdocuments.site/reader034/viewer/2022042112/5e8e046552395b744e22856d/html5/thumbnails/28.jpg)
28
Adjuvant Radiotherapy
• Two early trials using radiation alone• Post-operative XRT vs. surgery alone 3
yr OS 23 % vs 27 % • Intra-operative radiation vs surgery -
Mean survival 26.9 months vs. 30.8 month
6
![Page 29: Peri-operative Treatment for Gastric Cancer · Reasons for peri-operative • Significant benefit with 3 cycles of pre-operative chemotherapy • Post-operative patients may not be](https://reader034.vdocuments.site/reader034/viewer/2022042112/5e8e046552395b744e22856d/html5/thumbnails/29.jpg)
Adjuvant chemoradiationSWOG 9008 / INT 0116
55--FU/LVFU/LV RadiationRadiation 55--FU/LV x2FU/LV x2
45 Gy45 Gy
RARANDNDOMOM
R0R0--resectedresected
gastric gastric
adenocarcimoma adenocarcimoma
observationobservation
55--FU/LV 5FU/LV 5--FU/LVFU/LV
Macdonald et al., NEJM 2001; 345: 725-730
ChemotherapyLeucovorin 20mg/m2 d1-5, 5-FU 425mg/m2 d1-5, qd28Modification cycle 2: leucovorin 20mg/m2 d1-4, 5-FU 400mg/m2 d1-4Modification cycle 3: leucovorin 20mg/m2 d1-3, 5-FU 400mg/m2 d1-3
![Page 30: Peri-operative Treatment for Gastric Cancer · Reasons for peri-operative • Significant benefit with 3 cycles of pre-operative chemotherapy • Post-operative patients may not be](https://reader034.vdocuments.site/reader034/viewer/2022042112/5e8e046552395b744e22856d/html5/thumbnails/30.jpg)
![Page 31: Peri-operative Treatment for Gastric Cancer · Reasons for peri-operative • Significant benefit with 3 cycles of pre-operative chemotherapy • Post-operative patients may not be](https://reader034.vdocuments.site/reader034/viewer/2022042112/5e8e046552395b744e22856d/html5/thumbnails/31.jpg)
Surgical Details
• Eligibility:– Curative intent en bloc resection of the
tumor– Negative Margins– Recommended D2 – perigastric, celiac,
splenic, hepaticoartery and cardial lymph nodes
![Page 32: Peri-operative Treatment for Gastric Cancer · Reasons for peri-operative • Significant benefit with 3 cycles of pre-operative chemotherapy • Post-operative patients may not be](https://reader034.vdocuments.site/reader034/viewer/2022042112/5e8e046552395b744e22856d/html5/thumbnails/32.jpg)
Surgical Details
• Of the 552 patients whose records were reviewed
• D2 lymphadecotomy – 10% (52 pts)• D1 lymphadecotomy – 36% (199 pts)• D0 lymphadecotomy – 54%
![Page 33: Peri-operative Treatment for Gastric Cancer · Reasons for peri-operative • Significant benefit with 3 cycles of pre-operative chemotherapy • Post-operative patients may not be](https://reader034.vdocuments.site/reader034/viewer/2022042112/5e8e046552395b744e22856d/html5/thumbnails/33.jpg)
![Page 34: Peri-operative Treatment for Gastric Cancer · Reasons for peri-operative • Significant benefit with 3 cycles of pre-operative chemotherapy • Post-operative patients may not be](https://reader034.vdocuments.site/reader034/viewer/2022042112/5e8e046552395b744e22856d/html5/thumbnails/34.jpg)
Macdonald et al., NEJM 2001; 345: 725-730
Adjuvant chemoradiationSWOG 9008 / INT 0116
![Page 35: Peri-operative Treatment for Gastric Cancer · Reasons for peri-operative • Significant benefit with 3 cycles of pre-operative chemotherapy • Post-operative patients may not be](https://reader034.vdocuments.site/reader034/viewer/2022042112/5e8e046552395b744e22856d/html5/thumbnails/35.jpg)
Median OS:
Chemo XRT 36 mos
Surgery 27 mos
HR for death 1.35 p=0.005
Macdonald et al., NEJM 2001; 345: 725-730
Adjuvant chemoradiationSWOG 9008 / INT 0116
![Page 36: Peri-operative Treatment for Gastric Cancer · Reasons for peri-operative • Significant benefit with 3 cycles of pre-operative chemotherapy • Post-operative patients may not be](https://reader034.vdocuments.site/reader034/viewer/2022042112/5e8e046552395b744e22856d/html5/thumbnails/36.jpg)
Subset Analysis
• At 10 ys f/u – HR 1.32 for OS and 1.51 for DFS
• Sex, race, T and N stage, D-level of resection, tumor location, histology and Maruyama index
• Chemoradiation benefitted all subsets except women (HR 1.0) and diffuse histology (HR 0.97)
ASCO 2009, Abstract 4515
![Page 37: Peri-operative Treatment for Gastric Cancer · Reasons for peri-operative • Significant benefit with 3 cycles of pre-operative chemotherapy • Post-operative patients may not be](https://reader034.vdocuments.site/reader034/viewer/2022042112/5e8e046552395b744e22856d/html5/thumbnails/37.jpg)
3715
Conclusions
• ChemoXRT is recommended for resected gastric cancer
• Majority of patients - D0/D1 surgery• Reflection of current practice• Sub group analysis did not reflect a
difference between D0/D1/D2 resection• Small numbers
![Page 38: Peri-operative Treatment for Gastric Cancer · Reasons for peri-operative • Significant benefit with 3 cycles of pre-operative chemotherapy • Post-operative patients may not be](https://reader034.vdocuments.site/reader034/viewer/2022042112/5e8e046552395b744e22856d/html5/thumbnails/38.jpg)
Adjuvant S-1
St. II + IIID2-resectionR0n = 10592001-2004
RANDOM
chemotherapyS1: 1 yearchemotherapyS1: 1 year
observationobservation
Primary endpoint: survivalHR 0.70; ⟨=0.05; power = 80%
*S1 (Tegafur, Gimeracil, Oteracil): 80mg/m² d1-28, qd 43
ATCS-GC study
Sakuramoto S et al. N Engl J Med 2007;357:1810-1820
![Page 39: Peri-operative Treatment for Gastric Cancer · Reasons for peri-operative • Significant benefit with 3 cycles of pre-operative chemotherapy • Post-operative patients may not be](https://reader034.vdocuments.site/reader034/viewer/2022042112/5e8e046552395b744e22856d/html5/thumbnails/39.jpg)
The role of oral fluoropyrimidines: S-1
New oral DPD-inhibiting fluoropyrimidin,developed by Taiho (Japan), consisting of
Tegafur (FT), Gimeracil (CDHP) und Oteracil-Kalium (Oxo)in a molar ratio of 1 : 0.4 : 1
Tegafur (FT) Gimeracil (CDHP) Oteracil-K (Oxo)
+ +
![Page 40: Peri-operative Treatment for Gastric Cancer · Reasons for peri-operative • Significant benefit with 3 cycles of pre-operative chemotherapy • Post-operative patients may not be](https://reader034.vdocuments.site/reader034/viewer/2022042112/5e8e046552395b744e22856d/html5/thumbnails/40.jpg)
The role of oral fluoropyrimidines: S-1
Kubota T. Br J Cancer 2008; 98:1301.1304
![Page 41: Peri-operative Treatment for Gastric Cancer · Reasons for peri-operative • Significant benefit with 3 cycles of pre-operative chemotherapy • Post-operative patients may not be](https://reader034.vdocuments.site/reader034/viewer/2022042112/5e8e046552395b744e22856d/html5/thumbnails/41.jpg)
![Page 42: Peri-operative Treatment for Gastric Cancer · Reasons for peri-operative • Significant benefit with 3 cycles of pre-operative chemotherapy • Post-operative patients may not be](https://reader034.vdocuments.site/reader034/viewer/2022042112/5e8e046552395b744e22856d/html5/thumbnails/42.jpg)
![Page 43: Peri-operative Treatment for Gastric Cancer · Reasons for peri-operative • Significant benefit with 3 cycles of pre-operative chemotherapy • Post-operative patients may not be](https://reader034.vdocuments.site/reader034/viewer/2022042112/5e8e046552395b744e22856d/html5/thumbnails/43.jpg)
Adjuvant S-1
Sakuramoto S et al. N Engl J Med 2007;357:1810-1820
Relapse-free survival
HR = 0.62 (95% CI, 0.50 to 0.77)P<0.0013 yr RFS 72.2% vs. 59.6%
HR = 0.68 (95% CI, 0.52 to 0.87)P = 0.0033 yr OS 80.1% vs. 70.1%
Overall survival
![Page 44: Peri-operative Treatment for Gastric Cancer · Reasons for peri-operative • Significant benefit with 3 cycles of pre-operative chemotherapy • Post-operative patients may not be](https://reader034.vdocuments.site/reader034/viewer/2022042112/5e8e046552395b744e22856d/html5/thumbnails/44.jpg)
Adjuvant S-1
Sakuramoto S et al. N Engl J Med 2007;357:1810-1820
Pattern of relapse
![Page 45: Peri-operative Treatment for Gastric Cancer · Reasons for peri-operative • Significant benefit with 3 cycles of pre-operative chemotherapy • Post-operative patients may not be](https://reader034.vdocuments.site/reader034/viewer/2022042112/5e8e046552395b744e22856d/html5/thumbnails/45.jpg)
4523
Conclusions• Adjuvant S1 improves OS by approx.
10%• Majority of patients had D2 resection• May not be valid in D0/D1 resection• Asian vs. Western patients? - Several
studies showing that there does not appear to be a genetic difference
• When equivalent surgery performed -treatment outcomes similar
• S1 not approved in Canada
![Page 46: Peri-operative Treatment for Gastric Cancer · Reasons for peri-operative • Significant benefit with 3 cycles of pre-operative chemotherapy • Post-operative patients may not be](https://reader034.vdocuments.site/reader034/viewer/2022042112/5e8e046552395b744e22856d/html5/thumbnails/46.jpg)
Adjuvant Chemotherapy
Meta-analyses Studies(n)
Patients(n)
Odds ratio (CI)
Hermans 1993 11 2096 0.88 (0.78-1.08)
Earle 1999 13 1990 0.80 (0.66-0.97)
Mari 2000 21 3658 0.82 (0.75-0.89)
Janunger 2002 21 3962 0.84 (0.74-0.96)
MetaMeta--analyses: only borderline significance for adjuvant chemotherapyanalyses: only borderline significance for adjuvant chemotherapy..
Single studies: virtually all negative.Single studies: virtually all negative.
Subgroup analyses: stronger trend towards better survival with cSubgroup analyses: stronger trend towards better survival with chemotherapy in hemotherapy in lymph node + disease.lymph node + disease.
Lordick F & Siewert JR. Gastric Cancer 2005; 8: 78-85
![Page 47: Peri-operative Treatment for Gastric Cancer · Reasons for peri-operative • Significant benefit with 3 cycles of pre-operative chemotherapy • Post-operative patients may not be](https://reader034.vdocuments.site/reader034/viewer/2022042112/5e8e046552395b744e22856d/html5/thumbnails/47.jpg)
• Individual patient-level meta-analysis• 17 trials – 3838 patients representing
60% of targeted data• Median f/u 7 years
![Page 48: Peri-operative Treatment for Gastric Cancer · Reasons for peri-operative • Significant benefit with 3 cycles of pre-operative chemotherapy • Post-operative patients may not be](https://reader034.vdocuments.site/reader034/viewer/2022042112/5e8e046552395b744e22856d/html5/thumbnails/48.jpg)
![Page 49: Peri-operative Treatment for Gastric Cancer · Reasons for peri-operative • Significant benefit with 3 cycles of pre-operative chemotherapy • Post-operative patients may not be](https://reader034.vdocuments.site/reader034/viewer/2022042112/5e8e046552395b744e22856d/html5/thumbnails/49.jpg)
• Median OS 4.9 years surgery only vs 7.8 years in the adjuvant chemotherapy 5FU based chemotherapy
• HR for OS 0.82 p< 0.001 and DFS 0.82 p< 0.001
• 49.6% to 55.3% (5.8%) benefit at 5 years and 37.5% to 44.9% (7.4%) benefit at 10 years
![Page 50: Peri-operative Treatment for Gastric Cancer · Reasons for peri-operative • Significant benefit with 3 cycles of pre-operative chemotherapy • Post-operative patients may not be](https://reader034.vdocuments.site/reader034/viewer/2022042112/5e8e046552395b744e22856d/html5/thumbnails/50.jpg)
Peri-operative treatment Outcomes
![Page 51: Peri-operative Treatment for Gastric Cancer · Reasons for peri-operative • Significant benefit with 3 cycles of pre-operative chemotherapy • Post-operative patients may not be](https://reader034.vdocuments.site/reader034/viewer/2022042112/5e8e046552395b744e22856d/html5/thumbnails/51.jpg)
BC Experience
• Gastric/GE junction patients should be evaluated for consideration of peri-operative treatment
• If not deemed to be a candidate for pre-operative treatment – consider post-operative treatment
![Page 52: Peri-operative Treatment for Gastric Cancer · Reasons for peri-operative • Significant benefit with 3 cycles of pre-operative chemotherapy • Post-operative patients may not be](https://reader034.vdocuments.site/reader034/viewer/2022042112/5e8e046552395b744e22856d/html5/thumbnails/52.jpg)
Reasons for peri-operative
• Significant benefit with 3 cycles of pre-operative chemotherapy
• Post-operative patients may not be candidates for adjuvant treatment
• Neo-adjuvant therapy can downstage disease – aid with achieving R0 resection
• May weed out the poor performing patients (patients who progress on neo-adjuvant treatment – will surgery really salvage them?)
![Page 53: Peri-operative Treatment for Gastric Cancer · Reasons for peri-operative • Significant benefit with 3 cycles of pre-operative chemotherapy • Post-operative patients may not be](https://reader034.vdocuments.site/reader034/viewer/2022042112/5e8e046552395b744e22856d/html5/thumbnails/53.jpg)
BC Experience
• Post-operative options:– ChemoXRT preferred – if poorly tolerated –
try to complete the ChemoXRT portion– If anastomosis high, may not be suitable
for XRT as field too large– Consider for adjuvant chemotherapy
![Page 54: Peri-operative Treatment for Gastric Cancer · Reasons for peri-operative • Significant benefit with 3 cycles of pre-operative chemotherapy • Post-operative patients may not be](https://reader034.vdocuments.site/reader034/viewer/2022042112/5e8e046552395b744e22856d/html5/thumbnails/54.jpg)
![Page 55: Peri-operative Treatment for Gastric Cancer · Reasons for peri-operative • Significant benefit with 3 cycles of pre-operative chemotherapy • Post-operative patients may not be](https://reader034.vdocuments.site/reader034/viewer/2022042112/5e8e046552395b744e22856d/html5/thumbnails/55.jpg)
55
ECC ECCSurgery
Surgery ChemoXRT - currently 5FUFuture - ECC/CP with XRT or ECC/CP alone
Not eligible for XRT - consider 5FU based chemotherapy - ECC?
Surgery - D1 or D2 resection or > 15 lymph nodes
Gastric Cancer Treatment Scheme
If upfront surgery - bleeding, not eligible for chemotherapy
![Page 56: Peri-operative Treatment for Gastric Cancer · Reasons for peri-operative • Significant benefit with 3 cycles of pre-operative chemotherapy • Post-operative patients may not be](https://reader034.vdocuments.site/reader034/viewer/2022042112/5e8e046552395b744e22856d/html5/thumbnails/56.jpg)
56
Conclusions
• All patients with localized/resectable gastric cancer should be referred pre-operatively for consideration of peri-operative treatment
• Surgical management should include a minimum of 15 lymph nodes or D1 lymph node dissection
![Page 57: Peri-operative Treatment for Gastric Cancer · Reasons for peri-operative • Significant benefit with 3 cycles of pre-operative chemotherapy • Post-operative patients may not be](https://reader034.vdocuments.site/reader034/viewer/2022042112/5e8e046552395b744e22856d/html5/thumbnails/57.jpg)
Thank You!